心房細動の消去後の抗リズム薬 (5A研究)
Jean-François Roux1, Erica Zado, David J Callans
1Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Circulation
|September 10, 2009
まとめ
6週間の経験的抗リズム薬 (AAD) 療法により,心房細動 (AF) 後のアブレーションにより,心房不律と入院が著しく減少しました. この治療はよく耐えており,AF除去後の患者のアウトカムが改善されました.
科学分野:
- 心臓病学 心臓病学
- 電気生理学 電気生理学
- 薬理学 薬理学とは
背景:
- 心房不律症は,心房動 (AF) 収縮後の早期に頻繁に発生します.
- この研究では,これらの早期のアブレーション後の心律不整症の緩和に,実証的抗不整症薬 (AAD) 療法の有効性を調査しました.
研究 の 目的:
- 6週間の経験的抗リズム薬 (AAD) 治療がAF除去後の心房不律の発生率を減少させるかどうかを判断する.
- この予防的AAD療法の安全性と耐性を評価する.
主な方法:
- ランダム化比較試験で,AF切除を受けた110人の患者が参加した.
- 患者は,抽出後の最初の6週間に,経験的AAD治療または抗不律療法を受けることを割り当てられました.
- トランステレフォニックモニターによる継続的なモニタリングと6週間の臨床評価が採用されました.
主要な成果:
- AADグループでは,プライマリ複合エンドポイント (19%対42%;P=0.005) を経験した患者が少なくなった.
- AF>24時間または心律不良に関連した入院/心臓転換を含む臨床的に重要なイベントは,AAD群で減少しました (13%対28%;P=0.05).
- AAD治療は良好に耐えており,不耐性による薬物の中止において有意な差異はありませんでした.
結論:
- AF除去後の6週間の経験的抗リズム薬 (AAD) 治療は安全で効果的です.
- この戦略は,臨床的に重要な心房不律の発生を大幅に低減し,心臓転換と入院の必要性を軽減します.
関連する概念動画
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Disturbances in Heart Rhythm
5.3K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
5.3K
Dysrhythmias VI: Management of Dysrhythmias
597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597


